ࡱ> HG  T\pVelisage-10 B=K_8X@"1 Aptos Narrow1 Aptos Narrow1 Aptos Narrow1 Aptos Narrow1 Aptos Narrow1h6 Aptos Narrow1,6 Aptos Narrow16 Aptos Narrow16 Aptos Narrow1 Aptos Narrow1 Aptos Narrow14 Aptos Narrow14 Aptos Narrow1  Aptos Narrow1  Aptos Narrow1 Aptos Narrow1 Aptos Narrow1  Aptos Narrow1 Aptos Narrow1 Aptos Narrow1< Aptos Narrow1? Aptos Narrow1> Aptos Narrow1,8 Aptos Narrow18 Aptos Narrow1 Aptos Narrow1 Aptos Narrow14 Aptos Narrow1  Aptos Narrow1  Aptos Narrow1 Aptos Narrow1 Aptos Narrow1  Aptos Narrow"?"\ #,##0;"?"\ \-#,##0"?"\ #,##0;[Red]"?"\ \-#,##0 "?"\ #,##0.00;"?"\ \-#,##0.00%""?"\ #,##0.00;[Red]"?"\ \-#,##0.00;*8_ "?"\ * #,##0_ ;_ "?"\ * \-#,##0_ ;_ "?"\ * "-"_ ;_ @_ ,))_ * #,##0_ ;_ * \-#,##0_ ;_ * "-"_ ;_ @_ C,@_ "?"\ * #,##0.00_ ;_ "?"\ * \-#,##0.00_ ;_ "?"\ * "-"??_ ;_ @_ 4+1_ * #,##0.00_ ;_ * \-#,##0.00_ ;_ * "-"??_ ;_ @_ "?"#,##0;"?"\-#,##0"?"#,##0;[Red]"?"\-#,##0"?"#,##0.00;"?"\-#,##0.00!"?"#,##0.00;[Red]"?"\-#,##0.0052_ "?"* #,##0_ ;_ "?"* \-#,##0_ ;_ "?"* "-"_ ;_ @_ =:_ "?"* #,##0.00_ ;_ "?"* \-#,##0.00_ ;_ "?"* "-"??_ ;_ @_ \$#,##0_);\(\$#,##0\)\$#,##0_);[Red]\(\$#,##0\)\$#,##0.00_);\(\$#,##0.00\)# \$#,##0.00_);[Red]\(\$#,##0.00\)                                    A.I. + )     b   A.I.   A,I,  A~I~        @} @Y  }|          i     20% - Accent1A 20% - Accent1 % 20% - Accent2A" 20% - Accent2 % 20% - Accent3A& 20% - Accent3 % 20% - Accent4M* 20% - Accent4 ef % 20% - Accent6A2 20% - Accent6 % 20% - ?? 5%  40% - Accent1M 40% - Accent1 L % 40% - Accent3A' 40% - Accent3 % 40% - Accent5M/ 40% - Accent5 L % 40% - ?? 2%  40% - ?? 4%  40% - ?? 6%  60% - Accent1A 60% - Accent1 % 60% - Accent2A$ 60% - Accent2 % 60% - Accent3M( 60% - Accent3 23GY % 60% - Accent4M, 60% - Accent4 23a % 60% - Accent5M0 60% - Accent5 23m %! 60% - ?? 6% " Calculationi Calculation% # Comma$( Comma [0]%&Currency&. Currency [0] ' Heading 3( Heading 3 ( Heading 4( Heading 4)InputiInput ??v%  *NeutralANeutral  W%3Normal %+Noteb Note   ,OutputkOutput ???%????????? ???-$Percent.Title Title/??0?? 1?? 1?? 2?? 2?? 3??????4?? 4 5?? 1?? 6?? 2?? 7?? 3?? 8?? 4?? 9?? 5?? :?? 6?? ;?????? <?????? =??????83ffff̙3f3fff3f3f33333f33333Table S7  T f4NKgrl  dMbP?_*+%,[&ffffff?'ffffff?(?)?"[D S7333333?333333?U f  ,? ,? , , , , , , , , , , , , , , , , , , , , , , , , , , , , , ,O@GSupplementary Table 7. The results of KEGG analysis in TARGET data set.?geneSet? description ?size?overlap?expect?enrichmentRatio?pValue ?FDR?userIdhsa05034 Alcoholismf@,@;(@ @>y>I2)?|tHIST1H2AD;HIST1H2BJ;DRD2;HIST1H3D;HIST1H4D;HIST1H2AL;HIST1H3G;HDAC7;HIST2H4A;H2AFZ;HIST1H2BG;ADORA2A;CREB5;HIST2H2BFhsa05322$Systemic lupus erythematosus`@$@r@P 5 @>+ٱA?=ݳ?c[HIST1H2AD;HIST1H2BJ;HIST1H3D;HIST1H4D;HIST1H2AL;HIST1H3G;HIST2H4A;H2AFZ;HIST1H2BG;HIST2H2BFhsa04978Mineral absorptionI@@Uz?Cż@>FSweG?=ݳ?%MT1X;MT1F;MT1H;MT1M;MT1E;MT2Ahsa05203Viral carcinogenesis i@(@"9@-[K@VT?~y?aYCCND1;HIST1H2BJ;JAK3;CDKN2A;CDC20;HIST1H4D;HDAC7;HIST2H4A;HIST1H2BG;CREB5;HIST2H2BF;VDAC3hsa05166/'Human T-cell leukemia virus 1 infectiono@*@?8@P } @? nsp?WOCCND1;JAK3;AKT3;CDKN2A;CDC20;IL2RB;NFATC2;POLE3;MAD2L1;ADCY2;VDAC3;TGFBR2;IL2RAhsa04080/'Neuroactive ligand-receptor interactionPq@*@qE@ڊʆ@qiz? >?SKGZMA;F2R;HRH2;CNR1;GLP2R;DRD2;LTB4R;TACR1;GPR35;ADORA2A;GABRR3;S1PR2;CHRNA6hsa04659!Th17 cell differentiationZ@@>MV@R:jn@2.?p:x?4,JAK3;IL27RA;IL2RB;IL1RAP;NFATC2;TGFBR2;IL2RA hsa04151" PI3K-Akt signaling pathway  v@.@ JBXU@ X~R? CbU6ׁ? p:x?Y QCCND1;F2R;FGF7;JAK3;AKT3;ITGA9;LAMC1;LAMA4;IL2RB;NTF3;TSC2;EPOR;LAMB1;CREB5;IL2RA hsa04015 Rap1 signaling pathway i@$@ LѦ@ ! @ lIkPW? vC>?? 7F2R;FGF7;CNR1;AKT3;DRD2;VASP;RASSF5;ADORA2A;ADCY2;ARAP3 hsa05223" Non-small cell lung cancer P@@ u? 6J @ !"? vC>?% CCND1;JAK3;AKT3;CDKN2A;RASSF5 hsa05222 Small cell lung cancer @W@@ A[1? q@  ? vC>?) !CCND1;AKT3;LAMC1;LAMA4;CKS2;LAMB1 hsa05200 Pathways in cancer p@3@ O7&+&@ 4DH? 3P>? vC>?s kCCND1;F2R;FGF7;MITF;JAK3;AKT3;CDKN2A;LAMC1;LAMA4;IL2RB;CKS2;RASSF5;EPOR;LAMB1;BIRC5;ADCY2;TGFBR2;IL2RA;HES1hsa04662)!B cell receptor signaling pathwayQ@@/U?>ᥞL @')?vC>?%AKT3;LILRB3;BCL10;CD22;NFATC2hsa01522Endocrine resistanceX@@ >t@pA@ =Hϒ?vC>?,$CCND1;GPER1;AKT3;CDKN2A;CYP2D7;ADCY2hsa05218MelanomaR@@9T?yq @5#E0?vC>?#CCND1;FGF7;MITF;AKT3;CDKN2Ahsa04218Cellular senescenced@ @ծKk @~ -m@Zݕ?S/?91CCND1;AKT3;CDKN2A;TSC2;RASSF5;NFATC2;VDAC3;TGFBR2hsa04022"cGMP-PKG signaling pathway`d@ @ " @0|.T@{"?Jy?7/KCNMA1;PDE3A;AKT3;VASP;NFATC2;CREB5;ADCY2;VDAC3hsa04024cAMP signaling pathwayh@"@~kC @ҞG@ fS{?HJ4,?;3F2R;PDE3A;AKT3;DRD2;ADORA2A;CREB5;ADCY2;PDE4B;ARAP3hsa04512 ECM-receptor interactionT@@^zu:?Yv@V-?B?$SV2C;ITGA9;LAMC1;LAMA4;LAMB1hsa04911Insulin secretion@U@@(k="?7@2?" [g?'KCNMA1;SNAP25;CREB5;VAMP2;ADCY2hsa05032Morphine addictionV@@Xl0?N@>d)?Bo@7sy?&PDE3A;KCNJ3;GABRR3;ADCY2;PDE4Bhsa04380"Osteoclast differentiation`@@Dw%֝@lnff@^o?ص?,$MITF;AKT3;LILRB3;SIRPG;NFATC2;TGFBR2hsa04630"JAK-STAT signaling pathway@d@@C @ġ#@&?ص?/'CCND1;JAK3;IL27RA;AKT3;IL2RB;EPOR;IL2RAhsa05162Measles`@@u@@Mެ3Q?6$[P?)!CCND1;JAK3;AKT3;TACR1;IL2RB;IL2RAhsa049620(Vasopressin-regulated water reabsorptionF@@Uby)?~ s@pΩG?6$[P?RAB5A;CREB5;VAMP2hsa04115p53 signaling pathwayR@@9T?I@Eam?6$[P?CCND1;CDKN2A;EI24;TSC2hsa05212Pancreatic cancerR@@̴?[@].J?xB ? CCND1;AKT3;CDKN2A;TGFBR2hsa05220 Chronic myeloid leukemiaS@@Cn ??yS@tw)b?xB ? CCND1;AKT3;CDKN2A;TGFBR2hsa04360 Axon guidancee@@Cʙ @K7A?ߴ?xB ?3+EPHA6;NFATC2;SEMA6B;EPHA1;EFNB1;ABLIM3;SSH1hsa03060Protein export7@@Tr?V.<@qǮ?xB ? SRPRB;SEC61A1DlS ,! ," ,# ,$ ,% ,& ,' ,( ,) ,* ,+ ,, ,- ,. ,/ ,0 ,1 ,2 ,3 ,4 ,5 ,6 ,7 ,8 ,9 ,: ,; ,< ,= ,> ,? , hsa00510 N-Glycan biosynthesis H@@ #t? pA@ nӜH? xB ? STT3A;MGAT3;GANAB!hsa05161! Hepatitis B!b@@!!ؐ@!?!nD ?!xB ?+!#CCND1;AKT3;NFATC2;CREB5;BIRC5;VDAC3"hsa04979"Cholesterol metabolism"I@@"bO3#?"x&1h@"֥Y?"xB ?"SCARB1;LPL;VDAC3#hsa04725#Cholinergic synapse#\@@#PO1@~ #@#kDh?#xB ?%#AKT3;KCNJ3;CREB5;ADCY2;CHRNA6$hsa04977($ Vitamin digestion and absorption$8@@$[y`s?$b@$[ٵ?$xB ?$ SCARB1;PLB1%hsa05202/%'Transcriptional misregulation in cancer%@g@@%i[1@%Uݕ?%oن?%b8.?7%/MLLT3;HMGA2;MITF;HIST1H3D;IL2RB;HIST1H3G;TGFBR2&hsa04923-&%Regulation of lipolysis in adipocytes&K@@&Q,-?&I@&o1H>һ?&}s?&AKT3;ADCY2;MGLL'hsa05210'Colorectal cancer'U@@' y?'5^@'..ż?' zܨ/?'CCND1;AKT3;BIRC5;TGFBR2(hsa04211$(Longevity regulating pathway(@V@@(z}7?(@(dYu?~ (?(AKT3;TSC2;CREB5;ADCY2)hsa04658() Th1 and Th2 cell differentiation)W@@)Tr?)V.<@)6?~ )?)JAK3;IL2RB;NFATC2;IL2RA*hsa04510*Focal adhesion*h@@*~kC @*1oE?*Jn{A?~ *?/*'CCND1;AKT3;ITGA9;LAMC1;LAMA4;VASP;LAMB1+hsa04213$+Longevity regulating pathway+O@@+. @?+g@+;eB?~ +?+AKT3;SOD1;ADCY2,hsa05146, Amoebiasis,X@@,s`s@,?,h7?~ ,?,LAMC1;LAMA4;RAB5A;LAMB1-hsa04927(- Cortisol synthesis and secretion-P@@-Dw%֝?-lnff@-S%P?~ -?-SCARB1;CREB5;ADCY2.hsa03040. Spliceosome.`@@.<@.?1?.4P#qt?~ .?(. DDX23;SNRNP40;LSM7;PRPF3;PRPF38A/hsa04914//'Progesterone-mediated oocyte maturation/X@@/XPT@/(%؂-?/ܜ?~ /?!/AKT3;RPS6KA2;MAD2L1;ADCY20hsa0413010)SNARE interactions in vesicular transport0A@@0 nN?07@0%k¬ ?~ 0?0 GOSR2;VAMP21hsa002301Purine metabolism1e@@1Y1 @1R?1x̺+-?~ 1?*1"PDE3A;POLR1E;POLE3;ADCY2;PDE4B;AK22hsa04915"2Estrogen signaling pathway2 a@@2 x9vz@24UB?2,?)?~ 2?$2GPER1;AKT3;KCNJ3;CREB5;ADCY23hsa002403Pyrimidine metabolism3@Y@@3tO@3oۇ?3aeX?~ 3?3CTPS1;POLR1E;DPYS;POLE34hsa050204Prion diseases4A@@4R?~ 4p@4,?~ 4?4 LAMC1;SOD15hsa05165&5Human papillomavirus infection50u@$@50N @5N?5߇Fa?~ 5?@58CCND1;AKT3;ITGA9;LAMC1;LAMA4;HDAC7;TSC2;LAMB1;CREB5;HES16hsa052146Glioma6Q@@6/U?6A($?6(0?~ 6?6CCND1;AKT3;CDKN2A7hsa04514&7Cell adhesion molecules (CAMs)7b@@7!ؐ@7yq?79Stf?~ 7?#7ITGA9;CD22;CLDN6;CDH2;CADM18hsa049318Insulin resistance8Z@@8>MV@8B-)?8gQ#?~ 8? 8AKT3;PTPN1;CREB5;RPS6KA29hsa04020!9Calcium signaling pathway9f@@9 2$\@9}?9i:6Arrhythmogenic right ventricular cardiomyopathy (ARVC):R@@:9T?:?:=?~ :?:ITGA9;CACNA2D2;CDH2;hsa01524 ;Platinum drug resistance;@R@@;xMP?;P.̱?;ronN?~ ;?;AKT3;CDKN2A;BIRC5<hsa05163'<Human cytomegalovirus infection< l@@<Q5G@<-hsa04216> Ferroptosis>D@@>-1Kk?~ >-m@>.00?~ >?>SLC39A14;VDAC3?hsa05033?Nicotine addiction?D@@?-1Kk?~ ?-m@?.00?~ ??? GABRR3;CHRNA6D{l@ ,A ,B ,C ,D ,E ,F ,G ,H ,I ,J ,K ,L ,M ,N ,O ,P ,Q ,R ,S ,T ,U ,V ,W ,X ,Y ,Z ,[ ,\ ,] ,^ ,_ ,@hsa04918!@Thyroid hormone synthesis@R@@@j]?@z^G?@?~ @?@ASGR1;CREB5;ADCY2Ahsa04670,A$Leukocyte transendothelial migrationA\@@APO1@~ Ad@AQD?~ A?AVASP;RASSF5;CLDN6;TXKBhsa05219BBladder cancerBD@@B^zu:?B,fm7@B(=?~ B?B CCND1;CDKN2AChsa04714C ThermogenesisCl@@Cv0X@Cddz?C2+%?~ C?0C(CNR1;TSC2;KDM1A;CREB5;RPS6KA2;ADCY2;MGLLDhsa05145D ToxoplasmosisD@\@@DV]@DM!q>^p?D%-?~ D?DAKT3;LAMC1;LAMA4;LAMB1Ehsa04921"EOxytocin signaling pathwayEc@@ECn @E}R](?EC 6?~ E?)E!CCND1;KCNJ3;CACNA2D2;NFATC2;ADCY2Fhsa04934FCushing syndromeF@c@@F3 Id @~ F@?FC?~ F?'FCCND1;CDKN2A;SCARB1;CREB5;ADCY2Ghsa04152GAMPK signaling pathwayG^@@Gʈ@G5o?GDd ^?~ G?GCCND1;AKT3;TSC2;CREB5Hhsa04217H NecroptosisH@d@@HC @H\+n ?Hx?~ H?,H$HIST1H2AD;JAK3;HIST1H2AL;H2AFZ;VDAC3Ihsa00270*I"Cysteine and methionine metabolismIG@@IØ'?I+Kq?IQ]e?~ I?I MTAP;MAT1AJhsa04611JPlatelet activationJ^@@JA@JŨ$J?JG*G?~ J?JF2R;AKT3;VASP;ADCY2Khsa04110K Cell cycleK_@@K^ @@Kq?K)y?~ K?!KCCND1;CDKN2A;CDC20;MAD2L1Lhsa04114LOocyte meiosisL_@@L^ @@Lq?L)y?~ L?"LCDC20;RPS6KA2;MAD2L1;ADCY2Mhsa041413M+Protein processing in endoplasmic reticulumMd@@M0uF @M: ""?MFƎw?~ M?(M STT3A;HYOU1;HSPA4L;GANAB;SEC61A1Nhsa04913NOvarian steroidogenesisNH@@N#t?N(W|?Nz,?~ N?N SCARB1;ADCY2Ohsa05030OCocaine addictionOH@@O#t?O(W|?Oz,?~ O?O DRD2;CREB5Phsa00330'PArginine and proline metabolismPI@@PbO3#?PK7A?PY[?~ P?P CKMT2;PRODH2Qhsa04727QGABAergic synapseQV@@QUby)?~ Qc@Q}5?~ Q?QSLC38A2;GABRR3;ADCY2Rhsa00730RThiamine metabolismR0@?R՝?~ R!6{?~ T?T RAB5A;SOD1Uhsa04530UTight junctionU@e@@U(k=" @U7?U402?~ U?%UCCND1;VASP;ACTR3B;CLDN6;MYH14Vhsa04970VSalivary secretionVV@@V#?V5o?Vczk?~ V?VKCNMA1;VAMP2;ADCY2Whsa05414$WDilated cardiomyopathy (DCM)WV@@W#?W5o?Wczk?~ W?WITGA9;CACNA2D2;ADCY2Xhsa04926!XRelaxin signaling pathwayX@`@@XݛwM\G@XeF?Xɡo?~ X?XAKT3;CREB5;ADCY2;TGFBR2Yhsa00120&YPrimary bile acid biosynthesisY1@?YzN?Y7@Y/~W?~ Y?YCYP8B1Zhsa04728ZDopaminergic synapseZ``@@Z) ;s@Z ]?Z߳x(?~ Z?ZAKT3;DRD2;KCNJ3;CREB5[hsa03460[Fanconi anemia pathway[K@@[Q,-?[̨?[*;?~ [?[ POLN;HES1\hsa00770)\!Pantothenate and CoA biosynthesis\3@?\˞n ?\?yS@\@K՛?~ \? \DPYS]hsa04925+]#Aldosterone synthesis and secretion]X@@]s`s@]33W?]>,X?~ ]?]SCARB1;CREB5;ADCY2^hsa04640"^Hematopoietic cell lineage^@X@@^+E@~ ^ b@^Gn?~ ^?^CD22;EPOR;IL2RA_hsa05215_Prostate cancer_@X@@_+E@~ _ b@_Gn?~ _?_CCND1;AKT3;CREB5Dl` ,a ,b ,c ,d ,e ,`hsa04550@`8Signaling pathways regulating pluripotency of stem cells``a@@`f5@`JW~?`1co??~ `?`ESRRB;JAK3;AKT3;INHBAahsa05213aEndometrial canceraM@@a '?aR?a6xN~?~ a?a CCND1;AKT3bhsa047508b0Inflammatory mediator regulation of TRP channelsbX@@bXPT@b: ""?b>?~ b?bIL1RAP;TRPA1;ADCY2chsa04933<c4AGE-RAGE signaling pathway in diabetic complicationscX@@cXPT@c: ""?c>?~ c?cCCND1;AKT3;TGFBR2dhsa04370dVEGF signaling pathwaydM@@dF8?dIQ?dt;%?~ d?d AKT3;NFATC2ehsa04660)e!T cell receptor signaling pathwaye@Y@@etO@eme/?eu6rJ?~ e?eAKT3;BCL10;NFATC2d=K_8X>  Oh+'0x8@L X dp???QC@B@| ՜.+,00 8@ H ]  Table S7  Worksheets  !"#$%&'()*+,-./012345689:;<=>@ABCDEFRoot EntryF ]Book lSummaryInformation(7DocumentSummaryInformation8?